These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24140894)

  • 1. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
    González-Aparicio R; Moratalla R
    Neurobiol Dis; 2014 Feb; 62():416-25. PubMed ID: 24140894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
    Solís O; Espadas I; Del-Bel EA; Moratalla R
    Neurobiol Dis; 2015 Jan; 73():49-59. PubMed ID: 25281315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
    Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
    Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
    Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
    Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
    Solís O; García-Montes JR; Garcia-Sanz P; Herranz AS; Asensio MJ; Kang G; Hiroi N; Moratalla R
    Neurobiol Dis; 2017 Jun; 102():133-139. PubMed ID: 28315782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
    Morgese MG; Cassano T; Cuomo V; Giuffrida A
    Exp Neurol; 2007 Nov; 208(1):110-9. PubMed ID: 17900568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
    Padovan-Neto FE; Echeverry MB; Tumas V; Del-Bel EA
    Neuroscience; 2009 Mar; 159(3):927-35. PubMed ID: 19302833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
    Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.